Peringatan Keamanan

Docusate is not known to be carcinogenic or cause reproductive toxicity. It was not mutagenic in the Ames assay MSDS. Acute oral LD50 in rat is 1900 mg/kg MSDS.

Docusate

DB11089

small molecule approved

Deskripsi

Docusate, or dioctyl sulfosuccinate, is a stool softener indicated for the treatment of constipation^A32201. Docusate acts by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass ^L1801. Docusate can be orally or rectally administered. Docusate is on the World Health Organization's List of Essential Medicines^L5915. However the effectiveness of docusate in treating constipation remains unclear, as several studies report docusate to be no more effective than placebo for increasing the frequency of stool or stool softening A32200,A32202,A176987. Recently there has been pressure to stop prescribing docusate as it has been identified as an ineffective medicineA176972,A176987,L5912. Additionally, it does not appear to lessen symptoms associated with constipation such as abdominal cramps. Still docusate is available in over-the-counter products as a common laxative.

Struktur Molekul 2D

Berat 422.577

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Docusate is not absorbed systemicallyL1801,L5912. As the actions of docusate are local and it is not absorbed, the pharmacokinetic parameters are not available^L5912.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

If docusate is systemically absorbed, it undergoes biliary excretion L1801,L5912.

Interaksi Obat

391 Data

Tramadol	The therapeutic efficacy of Docusate can be decreased when used in combination with Tramadol.
Trospium	The therapeutic efficacy of Docusate can be decreased when used in combination with Trospium.
Oxyphenonium	The therapeutic efficacy of Docusate can be decreased when used in combination with Oxyphenonium.
Benzatropine	The therapeutic efficacy of Docusate can be decreased when used in combination with Benzatropine.
Ziprasidone	The therapeutic efficacy of Docusate can be decreased when used in combination with Ziprasidone.
Disopyramide	The therapeutic efficacy of Docusate can be decreased when used in combination with Disopyramide.
Amitriptyline	The therapeutic efficacy of Docusate can be decreased when used in combination with Amitriptyline.
Ipratropium	The therapeutic efficacy of Docusate can be decreased when used in combination with Ipratropium.
Olanzapine	The therapeutic efficacy of Docusate can be decreased when used in combination with Olanzapine.
Metixene	The therapeutic efficacy of Docusate can be decreased when used in combination with Metixene.
Terfenadine	The therapeutic efficacy of Docusate can be decreased when used in combination with Terfenadine.
Buclizine	The therapeutic efficacy of Docusate can be decreased when used in combination with Buclizine.
Clozapine	The therapeutic efficacy of Docusate can be decreased when used in combination with Clozapine.
Doxylamine	The therapeutic efficacy of Docusate can be decreased when used in combination with Doxylamine.
Trihexyphenidyl	The therapeutic efficacy of Docusate can be decreased when used in combination with Trihexyphenidyl.
Oxyphencyclimine	The therapeutic efficacy of Docusate can be decreased when used in combination with Oxyphencyclimine.
Procyclidine	The therapeutic efficacy of Docusate can be decreased when used in combination with Procyclidine.
Profenamine	The therapeutic efficacy of Docusate can be decreased when used in combination with Profenamine.
Promazine	The therapeutic efficacy of Docusate can be decreased when used in combination with Promazine.
Hyoscyamine	The therapeutic efficacy of Docusate can be decreased when used in combination with Hyoscyamine.
Cyproheptadine	The therapeutic efficacy of Docusate can be decreased when used in combination with Cyproheptadine.
Imipramine	The therapeutic efficacy of Docusate can be decreased when used in combination with Imipramine.
Methscopolamine bromide	The therapeutic efficacy of Docusate can be decreased when used in combination with Methscopolamine bromide.
Chlorpromazine	The therapeutic efficacy of Docusate can be decreased when used in combination with Chlorpromazine.
Gallamine triethiodide	The therapeutic efficacy of Docusate can be decreased when used in combination with Gallamine triethiodide.
Darifenacin	The therapeutic efficacy of Docusate can be decreased when used in combination with Darifenacin.
Tridihexethyl	The therapeutic efficacy of Docusate can be decreased when used in combination with Tridihexethyl.
Triflupromazine	The therapeutic efficacy of Docusate can be decreased when used in combination with Triflupromazine.
Anisotropine methylbromide	The therapeutic efficacy of Docusate can be decreased when used in combination with Anisotropine methylbromide.
Nortriptyline	The therapeutic efficacy of Docusate can be decreased when used in combination with Nortriptyline.
Amoxapine	The therapeutic efficacy of Docusate can be decreased when used in combination with Amoxapine.
Atropine	The therapeutic efficacy of Docusate can be decreased when used in combination with Atropine.
Nicardipine	The therapeutic efficacy of Docusate can be decreased when used in combination with Nicardipine.
Pirenzepine	The therapeutic efficacy of Docusate can be decreased when used in combination with Pirenzepine.
Paroxetine	The therapeutic efficacy of Docusate can be decreased when used in combination with Paroxetine.
Rocuronium	The therapeutic efficacy of Docusate can be decreased when used in combination with Rocuronium.
Scopolamine	The therapeutic efficacy of Docusate can be decreased when used in combination with Scopolamine.
Benzquinamide	The therapeutic efficacy of Docusate can be decreased when used in combination with Benzquinamide.
Clidinium	The therapeutic efficacy of Docusate can be decreased when used in combination with Clidinium.
Propiomazine	The therapeutic efficacy of Docusate can be decreased when used in combination with Propiomazine.
Propantheline	The therapeutic efficacy of Docusate can be decreased when used in combination with Propantheline.
Dicyclomine	The therapeutic efficacy of Docusate can be decreased when used in combination with Dicyclomine.
Biperiden	The therapeutic efficacy of Docusate can be decreased when used in combination with Biperiden.
Brompheniramine	The therapeutic efficacy of Docusate can be decreased when used in combination with Brompheniramine.
Flupentixol	The therapeutic efficacy of Docusate can be decreased when used in combination with Flupentixol.
Cocaine	The therapeutic efficacy of Docusate can be decreased when used in combination with Cocaine.
Quinidine	The therapeutic efficacy of Docusate can be decreased when used in combination with Quinidine.
Maprotiline	The therapeutic efficacy of Docusate can be decreased when used in combination with Maprotiline.
Methantheline	The therapeutic efficacy of Docusate can be decreased when used in combination with Methantheline.
Cycrimine	The therapeutic efficacy of Docusate can be decreased when used in combination with Cycrimine.
Glycopyrronium	The therapeutic efficacy of Docusate can be decreased when used in combination with Glycopyrronium.
Tolterodine	The therapeutic efficacy of Docusate can be decreased when used in combination with Tolterodine.
Oxybutynin	The therapeutic efficacy of Docusate can be decreased when used in combination with Oxybutynin.
Promethazine	The therapeutic efficacy of Docusate can be decreased when used in combination with Promethazine.
Diphenhydramine	The therapeutic efficacy of Docusate can be decreased when used in combination with Diphenhydramine.
Doxacurium	The therapeutic efficacy of Docusate can be decreased when used in combination with Doxacurium.
Doxepin	The therapeutic efficacy of Docusate can be decreased when used in combination with Doxepin.
Flavoxate	The therapeutic efficacy of Docusate can be decreased when used in combination with Flavoxate.
Desipramine	The therapeutic efficacy of Docusate can be decreased when used in combination with Desipramine.
Orphenadrine	The therapeutic efficacy of Docusate can be decreased when used in combination with Orphenadrine.
Escitalopram	The therapeutic efficacy of Docusate can be decreased when used in combination with Escitalopram.
Quetiapine	The therapeutic efficacy of Docusate can be decreased when used in combination with Quetiapine.
Mivacurium	The therapeutic efficacy of Docusate can be decreased when used in combination with Mivacurium.
Diphenidol	The therapeutic efficacy of Docusate can be decreased when used in combination with Diphenidol.
Aripiprazole	The therapeutic efficacy of Docusate can be decreased when used in combination with Aripiprazole.
Chlorprothixene	The therapeutic efficacy of Docusate can be decreased when used in combination with Chlorprothixene.
Metocurine	The therapeutic efficacy of Docusate can be decreased when used in combination with Metocurine.
Pancuronium	The therapeutic efficacy of Docusate can be decreased when used in combination with Pancuronium.
Pipecuronium	The therapeutic efficacy of Docusate can be decreased when used in combination with Pipecuronium.
Methotrimeprazine	The therapeutic efficacy of Docusate can be decreased when used in combination with Methotrimeprazine.
Tiotropium	The therapeutic efficacy of Docusate can be decreased when used in combination with Tiotropium.
Solifenacin	The therapeutic efficacy of Docusate can be decreased when used in combination with Solifenacin.
Isopropamide	The therapeutic efficacy of Docusate can be decreased when used in combination with Isopropamide.
Rapacuronium	The therapeutic efficacy of Docusate can be decreased when used in combination with Rapacuronium.
Mepenzolate	The therapeutic efficacy of Docusate can be decreased when used in combination with Mepenzolate.
Pizotifen	The therapeutic efficacy of Docusate can be decreased when used in combination with Pizotifen.
Fesoterodine	The therapeutic efficacy of Docusate can be decreased when used in combination with Fesoterodine.
Hexocyclium	The therapeutic efficacy of Docusate can be decreased when used in combination with Hexocyclium.
Dimetindene	The therapeutic efficacy of Docusate can be decreased when used in combination with Dimetindene.
Aclidinium	The therapeutic efficacy of Docusate can be decreased when used in combination with Aclidinium.
Dexetimide	The therapeutic efficacy of Docusate can be decreased when used in combination with Dexetimide.
Benactyzine	The therapeutic efficacy of Docusate can be decreased when used in combination with Benactyzine.
Umeclidinium	The therapeutic efficacy of Docusate can be decreased when used in combination with Umeclidinium.
Trimebutine	The therapeutic efficacy of Docusate can be decreased when used in combination with Trimebutine.
Dosulepin	The therapeutic efficacy of Docusate can be decreased when used in combination with Dosulepin.
Imidafenacin	The therapeutic efficacy of Docusate can be decreased when used in combination with Imidafenacin.
Butylscopolamine	The therapeutic efficacy of Docusate can be decreased when used in combination with Butylscopolamine.
Thonzylamine	The therapeutic efficacy of Docusate can be decreased when used in combination with Thonzylamine.
Methscopolamine	The therapeutic efficacy of Docusate can be decreased when used in combination with Methscopolamine.
Revefenacin	The therapeutic efficacy of Docusate can be decreased when used in combination with Revefenacin.
Oxitropium	The therapeutic efficacy of Docusate can be decreased when used in combination with Oxitropium.
Propiverine	The therapeutic efficacy of Docusate can be decreased when used in combination with Propiverine.
Batefenterol	The therapeutic efficacy of Docusate can be decreased when used in combination with Batefenterol.
Mebeverine	The therapeutic efficacy of Docusate can be decreased when used in combination with Mebeverine.
Tropatepine	The therapeutic efficacy of Docusate can be decreased when used in combination with Tropatepine.
Prifinium	The therapeutic efficacy of Docusate can be decreased when used in combination with Prifinium.
Piperidolate	The therapeutic efficacy of Docusate can be decreased when used in combination with Piperidolate.
Benzilone	The therapeutic efficacy of Docusate can be decreased when used in combination with Benzilone.
Difemerine	The therapeutic efficacy of Docusate can be decreased when used in combination with Difemerine.
Phenglutarimide	The therapeutic efficacy of Docusate can be decreased when used in combination with Phenglutarimide.

Referensi & Sumber

Artikel (PubMed)

PMID: 2414161
Moriarty KJ, Kelly MJ, Beetham R, Clark ML: Studies on the mechanism of action of dioctyl sodium sulphosuccinate in the human jejunum. Gut. 1985 Oct;26(10):1008-13.
PMID: 22889861
Tarumi Y, Wilson MP, Szafran O, Spooner GR: Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage. 2013 Jan;45(1):2-13. doi: 10.1016/j.jpainsymman.2012.02.008. Epub 2012 Aug 11.
PMID: 27154771
MacMillan TE, Kamali R, Cavalcanti RB: Missed Opportunity to Deprescribe: Docusate for Constipation in Medical Inpatients. Am J Med. 2016 Sep;129(9):1001.e1-7. doi: 10.1016/j.amjmed.2016.04.008. Epub 2016 May 3.
PMID: 9663731
McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M: Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998 May;12(5):491-7.
PMID: 10699540
Hurdon V, Viola R, Schroder C: How useful is docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. J Pain Symptom Manage. 2000 Feb;19(2):130-6.
PMID: 2410320
Chapman RW, Sillery J, Fontana DD, Matthys C, Saunders DR: Effect of oral dioctyl sodium sulfosuccinate on intake-output studies of human small and large intestine. Gastroenterology. 1985 Sep;89(3):489-93.

Link

Contoh Produk & Brand

Produk: 1228 • International brands: 11

Produk

2 In 1laxative Stool Softener and Stiulant Laxative

Tablet, coated • - • Oral • US • OTC
2 In 1laxative Stool Softener and Stiulant Laxative

Tablet, coated • - • Oral • US • OTC
Acidobyl

Tablet • - • Oral • Canada • OTC • Approved
Ag-docusate Sodium

Capsule • 100 mg • Oral • Canada • Generic • OTC • Approved
Albert Docusate

Capsule • 240 mg • Oral • Canada • OTC • Approved
Alta-docusate Sodium

Capsule • 100 mg • Oral • Canada • OTC • Approved
Apo-docusate Calcium

Capsule • 240 mg • Oral • Canada • Generic • OTC • Approved
Apo-docusate Sodium

Capsule • 100 mg • Oral • Canada • Generic • OTC • Approved

Menampilkan 8 dari 1228 produk.

International Brands

Audinorm
Clear ear
Colace
Correctol
Dialose
Docusol
Docusol 100
Doxinate
Dulcoease
Rectalad enema

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.